Direct Pharmacological Activation of AMPK Modestly Extends Life in Short-Lived Species
Key claim: Commentary argues that direct pharmacological AMPK activation still only modestly extends lifespan in short-lived species, matching the mixed and non-robust animal effects of indirect AMPK interventions such as metformin.
Abstract
AMPK is the target of a range of interventions known to modestly slow aging in short-lived species. Like much of the complex array of evolved machinery that responds to various forms of cellular stress with improved maintenance, repair of damage, and a consequent slowing of aging, AMPK is involved in the regulation of energy metabolism. Many of these interventions, such as metformin, are far from robust. The animal data is mixed. One might argue that this is in part because the effects on the behavior of AMPK are indirect, as researchers do in this paper. Still, their direct approach to activating AMPK still produces only a modest effect on life span, and does so in species known to be far more receptive to life extension […]
Why this matters
Commentary argues that direct pharmacological AMPK activation still only modestly extends lifespan in short-lived species, matching the mixed and non-robust animal effects of indirect AMPK interventions such as metformin.